SC 13G: Tevogen Bio Holdings Inc.
Ticker: TVGNW · Form: SC 13G · Filed: Mar 4, 2024 · CIK: 1860871
| Field | Detail |
|---|---|
| Company | Tevogen Bio Holdings Inc. (TVGNW) |
| Form Type | SC 13G |
| Filed Date | Mar 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Tevogen Bio Holdings Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Tevogen Bio Holdings Inc. (ticker: TVGNW) to the SEC on Mar 4, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
How long is this filing?
Tevogen Bio Holdings Inc.'s SC 13G filing is 3 pages with approximately 919 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 919 words · 4 min read · ~3 pages · Grade level 9.2 · Accepted 2024-03-04 16:24:14
Filing Documents
- tevogen13g.htm (SC 13G) — 81KB
- image2.jpg (GRAPHIC) — 40KB
- 0001123292-24-000067.txt ( ) — 138KB
(a)
Item 1(a) Name of Issuer : The name of the issuer is Tevogen Bio Holdings Inc. (the "Issuer").
(b)
Item 1(b) Address of Issuer's Principal Executive Offices : 15 Independence Boulevard, Suite #410, Warren, New Jersey 07059.
(a)
Item 2(a) Name of Person Filing : Manmohan Patel
(b)
Item 2(b) Address of Principal Business Office or, if none, Residence : 5 Jennie Court, Cedar Grove, NJ 07009
(c)
Item 2(c) Citizenship : United States
(d)
Item 2(d) Title of Class of Securities : Common Stock
(e)
Item 2(e) CUSIP No. : 88165K101 Item 3 If this statement is filed pursuant to 240.13d-l(b) or 240.13d-2(b) or (c), check whether the person filing is a : (a) Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ . Item 4 Tevogen Bio Holdings Inc. (a) Amount beneficially owned: 9,274,489 (b) Percent of class: 5.6% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 646,412 (ii) Shared power to vote or direct the vote: 8,628,077 (iii) Sole power to dispose or direct the disposition: 646,412 (iv) Shared power to dispose or direct the disposition: 8,628,077 Item 5 If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of th